A case of severe aplastic anaemia after SARS-CoV-2 vaccination

 

A case of severe aplastic anaemia after SARS-CoV-2 vaccination

There is increasing awareness about the possible relationship between severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccines and the development of haematological diseases, including autoimmune cytopenias (AICs) and complement-mediated diseases. Specifically, the development or recrudescence of autoimmune haemolytic anaemia,12 immune thrombocytopenia purpura34 and paroxysmal nocturnal haemoglobinuria (PNH)56 have been described secondarily to coronavirus disease 2019 (COVID-19) vaccines, regardless of the type. It has been reported that vaccines other than anti-SARS-CoV-2 could trigger AICs, as well as complement activation, although the matter is highly debated.78 Only few data have been reported regarding aplastic anaemia (AA) that is characterised by the premature death of bone marrow precursors due to a T-cell mediated immune attack. AA may be primary or secondary to several triggers, and a number of cases developing or relapsing after vaccine for hepatitis B virus (HBV), H1N1 influenza, varicella-zoster virus have been described.915 Here we report the first case of acquired AA developing after the administration of SARS-CoV-2 Pfizer-Biontech mRNA vaccine.

In April 2021 a 76-year-old male was admitted to a local hospital because of the sudden onset of haematomas and epistaxis. His personal past and family medical history were unremarkable. The patient had never had symptoms of cytopenia (i.e. pallor, fatigue, jaundice, bleeding, or harmful/frequent infections), and blood counts from ˜1 year before presentation were within the normal range. He had completed the SARS-CoV-2 Pfizer-Biontech vaccination schedule in March (Fig 1). At 1 month after the second dose, he developed asthenia and muco-cutaneous bleeding. At admission, laboratory tests found severe thrombocytopenia [platelet count (PLT) 3 × 109/l], confirmed in sodium-citrate, leucopenia (white blood cells 3.7 × 109/l) with severe neutropenia [absolute neutrophil count (ANC) 0·46 × 109/l), and mild normocytic anaemia [haemoglobin (Hb) 112 g/l]. Haemolytic markers were normal except for a slight lactate dehydrogenase increase (1·1 × upper limit of normal). Reticulocytes were low (38 × 109/l), and serum erythropoietin levels increased (308 mu/ml). Vitamins and iron status, coagulation tests, serum electrophoresis, and total immunoglobulins (Igs) were within the normal ranges. Blood smear showed no schistocytes nor blasts. Serology for HBV, human immunodeficiency virus, hepatitis C virus and Epstein–Barr virus was negative, whilst cytomegalovirus (CMV) and parvovirus B-19 IgG were positive (DNA negative). Autoimmune tests were all negative, including direct anti-globulin test (DAT), anti-nuclear antibodies (ANA), extractable nuclear antigen (ENA), p- and c-anti-neutrophil cytoplasmic antibodies (p-ANCA, c-ANCA). Bone marrow aspirate and biopsy showed 10% cellularity in absence of blasts or dysplastic features, and normal cytogenetics. Flow cytometry revealed the presence of a small PNH clone of 0·6% on granulocytes and 0·03% on erythrocytes. The diagnosis of severe AA (SAA) according to Camitta criteria was established, and the patient started on steroids (prednisone 1 mg/kg/day) and platelets transfusions with no response. Due to worsening pancytopenia (Hb 88 g/l, ANC 0.9 × 109/l, PLT 10 × 109/l) he was then referred to our Centre (May 2021) and treated with immunosuppressive therapy (IST, cyclosporin 3 mg/kg/day + rabbit anti-thymocyte globulin, ATG). At 15 days after ATG, the patient developed fever and severe right knee arthritis interpreted as serum sickness and managed at first with high-dose steroids. Thereafter, synovial liquid culture turned positive for Pseudomonas aeruginosa, and CMV reactivation occurred, requiring intravenous antibiotic and anti-viral therapy, with progressive resolution of the clinical picture. At last follow-up the patient was still severely pancytopenic and transfusion-dependent (Hb 82 g/l, ANC 0·58 × 109/l, PLT 18 × 109/l, after transfusion).

In conclusion, SARS-CoV-2 vaccine may be associated with the development and/or exacerbation of both peripheral AICs and central AA, either as the single trigger or by disclosing a latent autoimmunity. Clinical awareness is fundamental to guide the evaluation of patients developing signs/symptoms suggestive of cytopenias after SARS-CoV-2 vaccine and to promptly establish the diagnosis and treatment of even rare haematological conditions. In any case, the several reports of AIC and AA complications caused by COVID-19 infection should be taken into consideration when weighing the risks/benefits of COVID-19 vaccination.


READ FULL TEXT HERE: https://onlinelibrary.wiley.com/doi/10.1111/bjh.17947

Commenti

Post popolari in questo blog

Il Nuovo Ordine Tecnologico: L'Ascesa dell'Intelligenza Artificiale nel Governo Americano... in linea con AGENDA 2030?

CTS e AstraZeneca: decisioni tra politica, pressione mediatica e scienza ignorata..

CTS, vaccini e politica: cosa emerse davvero nella riunione del 12 maggio 2021 - ANALISI DELLA DISCUSSIONE